



November 2, 2015

## **Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference and Webcast**

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2015 financial results, provide an update on the Company's business, and discuss expectations for the future.

### **Conference Call**

#### **Wednesday, November 4, 2015 @ 4:30 p.m. Eastern/1:30 p.m. Pacific**

Domestic: (877) 837-3910, Conference ID# 54872723

International: (973) 796-5077, Conference ID# 54872723

For interested individuals unable to join the call, a replay will be available from November 4, 2015 @ 7:30 p.m. ET/4:30 p.m. PT through November 17, 2015 until 11:59 p.m. ET/8:59 p.m. PT.

Domestic Replay Dial-In #: (855) 859-2056, Conference ID# 54872723

International Replay Dial-In #: (404) 537-3406, Conference ID#54872723

This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: [www.sppirx.com](http://www.sppirx.com) on November 4, 2015 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

### **About Spectrum Pharmaceuticals, Inc.**

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Oncology and Hematology. Spectrum and its affiliates market five oncology drugs— FUSILEV<sup>®</sup> (levoleucovorin) for Injection in the U.S.; FOLOTYN<sup>®</sup> (pralatrexate injection), also marketed in the U.S.; ZEVALIN<sup>®</sup> (ibrutinomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; MARQIBO<sup>®</sup> (vinCRISStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights, and BELEODAQ<sup>®</sup> (belinostat) for Injection in the U.S. Additionally, Spectrum's pipeline includes two drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise and proven track record in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at [www.sppirx.com](http://www.sppirx.com).

*Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.*

*SPECTRUM PHARMACEUTICALS, INC.*<sup>®</sup>, *FUSILEV*<sup>®</sup>, *FOLOTYN*<sup>®</sup>, *ZEVALIN*<sup>®</sup>, *MARQIBO*<sup>®</sup>, and *BELEODAQ*<sup>®</sup> are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates. *REDEFINING CANCER CARE*<sup>™</sup>, *EVOMELA*<sup>™</sup> and *Spectrum Pharmaceuticals* logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20151102005360/en/>

Spectrum Pharmaceuticals, Inc.  
Shiv Kapoor, 702-835-6300  
Vice President, Strategic Planning & Investor Relations  
[InvestorRelations@sppirx.com](mailto:InvestorRelations@sppirx.com)

Source: Spectrum Pharmaceuticals, Inc.

News Provided by Acquire Media